Cerevance’s attempt to unlock the first-line Parkinson's disease market has hit a snag, with solengepras performing no better ...
Clinical Trials Arena on MSN2d
Cerevance to proceed with Phase III Parkinson’s trial despite Phase II setbackThe pivotal, Phase III study will evaluate the change in average daily “OFF” time in solengepras patients compared to placebo ...
The ASCEND trial evaluated the safety, tolerability, and efficacy of solengepras and aimed to establish its potential to ...
Solengepras, the most advanced investigational treatment in Cerevance's pipeline, is an oral, non-dopaminergic therapy in Phase 3 development for Parkinson's disease. A brain-penetrant, specific ...
Cerevance has said it plans to move on to late-stage trials of its first-in-class Parkinson's disease drug CVN424 after hitting the mark in a phase 2 proof-of-concept study. The Boston-based ...
UK-based clinical-stage biopharmaceutical company Cerevance has announced top-line results from the Phase II ASCEND trial of solengepras as an investigational monotherapy in patients with early, ...
Merck is paying $25 million upfront to tap into Cerevance's NETSseq transcriptomics technology, used to discover proteins that are either over- or under-expressed in disease states, and is also ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback